Protagonist Therapeutics
PTGX
140.92
+2.23
+1.61%
Protagonist Therapeutics
US · PTGX
#1570 by market cap
Listed 2016
140.92
+2.23
+1.61%
Live - 5344 symbols - heartbeat 137s ago
· 2026-10-08 09:20
Pre-market
139.71
-0.86%
After-hours
140.92
0.00%
- Market cap
- 9.12B
- P/E (TTM)i
- 136.82
- P/Bi
- 10.84
- EPSi
- -2.05
- Div yieldi
- 0.00%
- 52W posi
- 77%
Reader sentiment
Are you bullish or bearish on PTGX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 11 analysts
Buy
Avg price target
171.60 +21.8%
Price target rangecurrent 140.92
Low149.00
Avg171.60
High186.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-09 | Citi | -- | BUY | 182.00 |
| 2026-09-01 | Truist Financial | -- | BUY | -- |
| 2026-09-01 | Citi | -- | BUY | 182.00 |
| 2026-09-01 | H.C. Wainwright | -- | BUY | 170.00 |
| 2026-08-31 | Wedbush | -- | BUY | 173.00 |
| 2026-08-31 | Citizens JMP | -- | BUY | 170.00 |
| 2026-08-31 | Clear Street | -- | BUY | 173.00 |
| 2026-08-31 | Citi | -- | BUY | 182.00 |
| 2026-08-31 | Goldman Sachs | -- | BUY | 186.00 |
| 2026-08-31 | H.C. Wainwright | -- | BUY | 170.00 |
| 2026-08-31 | Barclays | -- | BUY | 180.00 |
| 2026-08-31 | J.P. Morgan | -- | BUY | 149.00 |
| 2026-08-30 | BMO Capital | -- | BUY | 178.00 |
| 2026-08-17 | BMO Capital | -- | BUY | 178.00 |
| 2026-08-12 | J.P. Morgan | -- | BUY | 149.00 |
| 2026-08-11 | Goldman Sachs | -- | BUY | 186.00 |
| 2026-08-10 | Truist Financial | -- | BUY | 170.00 |
| 2026-08-10 | Wedbush | -- | BUY | 173.00 |
| 2026-08-10 | Goldman Sachs | -- | BUY | 186.00 |
| 2026-08-10 | H.C. Wainwright | -- | BUY | 167.00 |
| 2026-08-07 | H.C. Wainwright | -- | BUY | 167.00 |
| 2026-08-06 | Clear Street | -- | BUY | 173.00 |
| 2026-08-06 | Citi | -- | BUY | 175.00 |
| 2026-08-06 | H.C. Wainwright | -- | BUY | 167.00 |
| 2026-08-06 | Barclays | -- | BUY | 153.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Goldman Sachs moved from Hold to Buy on 2026-08-10.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-08-10 | Goldman Sachs | HOLD → BUY | 186.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2020/Q4 | 2021-03-10 | After close | ±15.77% | +4.09% (in line) |
| 2020/Q1 | 2020-05-07 | -- | -- | +83.70% |
| 2019/Q4 | 2020-03-10 | After close | -- | -6.16% |
| 2018/Q4 | 2019-03-12 | After close | -- | -1.46% |
| 2017/Q4 | 2018-03-07 | After close | -- | -3.16% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 09:20:10 · For reference only, not investment advice and not tailored to your situation.